imiquimod has been researched along with paromomycin in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (60.00) | 29.6817 |
2010's | 2 (40.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Berman, J | 1 |
Bazarsky, E; El-On, J; Sneir, R | 1 |
Minodier, P; Parola, P | 1 |
Aguiar, MG; Carneiro, G; Fernandes, AP; Ferreira, LA | 1 |
Blanco, L; Calvo, A; Espuelas, S; Fernández-Rubio, C; Irache, JM; Larrea, E; Moreno, E; Nguewa, P; Sanmartín, C; Schwartz, J | 1 |
3 review(s) available for imiquimod and paromomycin
Article | Year |
---|---|
Clinical status of agents being developed for leishmaniasis.
Topics: Aminoquinolines; Antiprotozoal Agents; Fluconazole; Humans; Imiquimod; Ketoconazole; Leishmaniasis; Paromomycin; Phosphorylcholine | 2005 |
Cutaneous leishmaniasis treatment.
Topics: Administration, Cutaneous; Administration, Oral; Aminoquinolines; Amphotericin B; Animals; Antimony; Antiprotozoal Agents; Humans; Imiquimod; Injections, Intralesional; Injections, Intramuscular; Leishmaniasis, Cutaneous; Paromomycin; Pentamidine; Phosphorylcholine | 2007 |
Drug delivery systems for the topical treatment of cutaneous leishmaniasis.
Topics: Administration, Cutaneous; Aminoquinolines; Amphotericin B; Animals; Antiprotozoal Agents; Drug Delivery Systems; Humans; Imiquimod; Leishmaniasis, Cutaneous; Naphthoquinones; Paromomycin; Phosphorylcholine; Skin Absorption | 2012 |
2 other study(ies) available for imiquimod and paromomycin
Article | Year |
---|---|
Leishmania major: in vitro and in vivo anti-leishmanial activity of paromomycin ointment (Leshcutan) combined with the immunomodulator Imiquimod.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Antiprotozoal Agents; Benzethonium; Drug Therapy, Combination; Imiquimod; Leishmania major; Leishmaniasis, Cutaneous; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Ointments; Paromomycin; Rabbits | 2007 |
Combination of paromomycin plus human anti-TNF-α antibodies to control the local inflammatory response in BALB/ mice with cutaneous leishmaniasis lesions.
Topics: Animals; Antibodies; Antiprotozoal Agents; Cells, Cultured; Dermatitis; Disease Models, Animal; Drug Therapy, Combination; Female; Host-Pathogen Interactions; Imiquimod; Inflammation Mediators; Leishmania major; Leishmaniasis, Cutaneous; Macrophages; Mice, Inbred BALB C; Neutrophil Infiltration; Paromomycin; Skin; Tumor Necrosis Factor-alpha | 2018 |